Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![MarcJacksonLA Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::4058194633.png) stock scope [@MarcJacksonLA](/creator/twitter/MarcJacksonLA) on x 7096 followers
Created: 2025-07-17 05:55:01 UTC

$IVBIY 
- Nature Medicine Published Phase X Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma -


![](https://pbs.twimg.com/card_img/1945235134443347968/tBp_EHPJ?format=png&name=600x314)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945723895728033992/c:line.svg)

**Related Topics**
[$1801hk](/topic/$1801hk)
[$ivbiy](/topic/$ivbiy)

[Post Link](https://x.com/MarcJacksonLA/status/1945723895728033992)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

MarcJacksonLA Avatar stock scope @MarcJacksonLA on x 7096 followers Created: 2025-07-17 05:55:01 UTC

$IVBIY

  • Nature Medicine Published Phase X Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma -

XXX engagements

Engagements Line Chart

Related Topics $1801hk $ivbiy

Post Link

post/tweet::1945723895728033992
/post/tweet::1945723895728033992